Halozyme Therapeutics Inc (HALO)

[rod5247]

"Bococizumab (PF-04950615, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor) -- Pfizer increased the target number of patients to be enrolled into its two cardiovascular outcomes trials for bococizumab from 18,300 to approximately 26,000. This expansion was undertaken to help ensure timely completion of these trials. While difficult to predict the exact timing for the completion of these event-driven trials, Pfizer believes primary completion of its studies will be in line with other PCSK9 cardiovascular outcome trials being conducted by certain other companies."

From Q3 PR